Recent Finacing
Recent Raise
SutroVax develops multivalent conjugate and complex-antigen vaccines using Sutro Biopharma’s Xpress CF cell-free protein synthesis platform for site-specific antigen–carrier conjugation, targeting broad-spectrum pneumococcal and Group A Strep vaccines.
